1.

Difference in Clinical Phenotype, Mutation Position, and Structural Change of RNF213 Rare Variants Between Pediatric and Adult Japanese Patients with Moyamoya Disease.

Nomura S, Akagawa H, Yamaguchi K, Azuma K, Nakamura A, Fukui A, Matsuzawa F, Aihara Y, Ishikawa T, Moteki Y, Chiba K, Hashimoto K, Morita S, Ishiguro T, Okada Y, Vetiska S, Andrade-Barazarte H, Radovanovic I, Kawashima A, Kawamata T.

Transl Stroke Res. 2023 Sep 28. Epub ahead of print. PMID: 37768541.

2.

Genotype-Structure-Phenotype Correlations of Disease-Associated IGF1R Variants and Similarities to Those of INSR Variants.

Hosoe J, Kawashima-Sonoyama Y, Miya F, Kadowaki H, Suzuki K, Kato T, Matsuzawa F, Aikawa SI, Okada Y, Tsunoda T, Hanaki K, Kanzaki S, Shojima N, Yamauchi T, Kadowaki T.

Diabetes. 2021 70(8):1874-1884. PMID: 34074726

3.

Clinical usefulness of multigene screening with phenotype-driven bioinformatics analysis for the diagnosis of patients with monogenic diabetes or severe insulin resistance.

Hosoe J, Miya F, Kadowaki H, Fujiwara T, Suzuki K, Kato T, Waki H, Sasako T, Aizu K, Yamamura N, Sasaki F, Kurano M, Hara K, Tanaka M, Ishiura H, Tsuji S, Honda K, Yoshimura J, Morishita S, Matsuzawa F, Aikawa SI, Boroevich KA, Nangaku M, Okada Y, Tsunoda T, Shojima N, Yamauchi T, Kadowaki T.

Diabetes Res Clin Pract. 2020 Nov;169:108461. PMID: 32971154

4.

A variant in the RP1L1 gene in a family with occult macular dystrophy in a predicted intrinsically disordered region.

Hiraoka M, Ishikawa A, Matsuzawa F, Aikawa SI, Sakurai A.

Ophthalmic Genet. 2020 Dec;41(6):599-605. PMID: 32940107

5.

Esterification of side-chain oxysterols by lysosomal phospholipase A2.

Abe A, Hiraoka M, Matsuzawa F, Aikawa SI, Niimura Y.

Biochim Biophys Acta Mol Cell Biol Lipids. 2020 Oct;1865(10):158787   PMID: 32777483

6.

Structural modeling and mutagenesis of endo-β-N-acetylglucosaminidase from Ogataea minuta identifies the importance of Trp295 for hydrolytic activity.

Kitajima T, Jia Y, Komatsuzaki A, Cui J, Matsuzawa F, Aikawa SI, Gao XD, Chiba Y.

J Biosci Bioeng. 2018 Feb;125(2):168-174. PMID: 28903882

7.

Inhibitory effects and specificity of synthetic sialyldendrimers toward recombinant human cytosolic sialidase 2 (NEU2).

Rahman MM, Kitao S, Tsuji D, Suzuki K, Sakamoto J, Matsuoka K, Matsuzawa F, Aikawa S, Itoh K.

Glycobiology. 2013 Apr;23(4):495-504. PMID: 23363739

8.

Introduction of an N-glycan sequon into HEXA enhances human beta-hexosaminidase cellular uptake in a model of Sandhoff disease.

Matsuoka K, Tsuji D, Aikawa S, Matsuzawa F, Sakuraba H, Itoh K.

Mol Ther. 18(8), 1519-1526 (2010)   PMID: 20571546

9.

Binding parameters and thermodynamics of the interaction of imino sugars with a recombinant human acid alpha-glucosidase (alglucosidase alfa): insight into the complex formation mechanism.

Yoshimizu M, Tajima Y, Matsuzawa F, Aikawa S, Iwamoto K, Kobayashi T, Edmunds T, Fujishima K, Tsuji D, Itoh K, Ikekita M, Kawashima I, Sugawara K, Ohyanagi N, Suzuki T, Togawa T, Ohno K, Sakuraba H.

Clin Chim Acta. 391(1-2), 68-73 (2008)  PMID: 18328816

10.

Phosphorylation-induced conformational switching of CPI-17 produces a potent myosin phosphatase inhibitor.

Eto M, Kitazawa T, Matsuzawa F, Aikawa S, Kirkbride JA, Isozumi N, Nishimura Y, Brautigan DL, Ohki SY.

Structure. 15(12), 1591-1602 (2007)   PMID: 18073109

11.

Structural and biochemical studies on Pompe disease and a "pseudodeficiency of acid alpha-glucosidase".

Tajima Y, Matsuzawa F, Aikawa S, Okumiya T, Yoshimizu M, Tsukimura T, Ikekita M, Tsujino S, Tsuji A, Edmunds T, Sakuraba H.

J Hum Genet. 52(11), 898-906 (2007)   PMID: 17805474

12.

Molecular pathologies of and enzyme replacement therapies for lysosomal diseases.

Sakuraba H, Sawada M, Matsuzawa F, Aikawa S, Chiba Y, Jigami Y, Itoh K.

CNS Neurol Disord Drug Targets. 5(4), 401-413 (2006) Review.   PMID: 16918392

13.

Prediction of the mechanism of action of omuralide (clasto-lactacystin beta-lactone) on human cathepsin A based on a structural model of the yeast proteasome beta5/PRE2-subunit/omuralide complex.

Aikawa S, Matsuzawa F, Satoh Y, Kadota Y, Doi H, Itoh K.

Biochim Biophys Acta. 1764(8), 1372-1380 (2006)   PMID: 16870514

14.

Phospho-pivot modeling predicts specific interactions of protein phosphatase-1 with a phospho-inhibitor protein CPI-17.

Matsuzawa F, Aikawa SI, Ohki SY, Eto M.

J Biochem. 137(5), 633-641 (2005)   PMID: 15944417

15.

Fabry disease: correlation between structural changes in alpha-galactosidase, and clinical and biochemical phenotypes.

Matsuzawa F, Aikawa S, Doi H, Okumiya T, Sakuraba H.

Hum Genet. 117(4), 317-328 (2005)   PMID: 15924232

16.

Critical regions for assembly of vertebrate nonmuscle myosin II.

Nakasawa T, Takahashi M, Matsuzawa F, Aikawa S, Togashi Y, Saitoh T, Yamagishi A, Yazawa M.

Biochemistry. 44(1), 174-183 (2005)  PMID: 15628858

17.

Three dimensional structural studies of alpha-N-acetylgalactosaminidase (alpha-NAGA) in alpha-NAGA deficiency (Kanzaki disease): different gene mutations cause peculiar structural changes in alpha-NAGAs resulting in different substrate specificities and clinical phenotypes.

Kanekura T, Sakuraba H, Matsuzawa F, Aikawa S, Doi H, Hirabayashi Y, Yoshii N, Fukushige T, Kanzaki T.

J Dermatol Sci. 37(1), 15-20 (2005)    PMID: 15619430

18.

Microbial serine carboxypeptidase inhibitors--comparative analysis of actions on homologous enzymes derived from man, yeast and wheat.

Satoh Y, Kadota Y, Oheda Y, Kuwahara J, Aikawa S, Matsuzawa F, Doi H, Aoyagi T, Sakuraba H, Itoh K.

J Antibiot (Tokyo). 57(5), 316-325 (2004)    PMID: 15303492

19.

Structural and immunocytochemical studies on alpha-N-acetylgalactosaminidase deficiency (Schindler/Kanzaki disease).

Sakuraba H, Matsuzawa F, Aikawa S, Doi H, Kotani M, Nakada H, Fukushige T, Kanzaki T.

J Hum Genet. 49(1), 1-8 (2004)    PMID: 14685826

20.

Structural basis of the GM2 gangliosidosis B variant.

Matsuzawa F, Aikawa S, Sakuraba H, Lan HT, Tanaka A, Ohno K, Sugimoto Y, Ninomiya H, Doi H.

J Hum Genet. 48(11), 582-589 (2003)     PMID: 14577003

21.

Molecular and structural studies of the GM2 gangliosidosis 0 variant.

Sakuraba H, Matsuzawa F, Aikawa S, Doi H, Kotani M, Lin H, Ohno K, Tanaka A, Yamada H, Uyama E.

J Hum Genet. 47(4), 176-183 (2002)    PMID: 12166653

22.

Novel missense mutations in the human lysosomal sialidase gene in sialidosis patients and prediction of structural alterations of mutant enzymes.

Itoh K, Naganawa Y, Matsuzawa F, Aikawa S, Doi H, Sasagasako N, Yamada T, Kira J, Kobayashi T, Pshezhetsky AV, Sakuraba H.

J Hum Genet. 47(1), 29-37 (2002)    PMID: 11829139

23.

Bcl-2 antiapoptotic protein mediates verotoxin II-induced cell death: possible association between bcl-2 and tissue failure by E. coli O157:H7.

Suzuki A, Doi H, Matsuzawa F, Aikawa S, Takiguchi K, Kawano H, Hayashida M, Ohno S.

Genes Dev. 14(14), 1734-1740 (2000)   PMID: 10898788 

24.

Actin-actin contact: chemical cross-linking between actin and the 2.6-kDa peptide from subdomain 4 of actin.

Hori K, Morita F, Matsuzawa F, Aikawa S.

J Biochem. 118(6), 1232-1238 (1995)   PMID: 8720140

25.

Diverse incidences of individual oligopeptides (dipeptidic to hexapeptidic) in proteins of human, bakers' yeast, and Escherichia coli origin registered in the Swiss-Prot data base.

Doi H, Kitajima M, Watanabe I, Kikuchi Y, Matsuzawa F, Aikawa S, Takiguchi K, Ohno S.

Proc Natl Acad Sci U S A. 92(7), 2879-83 (1995)    PMID: 7708741